Substrate independent silver nanoparticle based antibacterial coatings

Biomaterials

Volumn 35, Issue 16, 2014, Pages 4601-4609

  Taheri, Shima ^a   Cavallaro, Alex ^a   Christo, Susan N ^a   Smith, Louise E ^a   Majewski, Peter ^a   Barton, Mary ^a   Hayball, John D ^a   Vasilev, Krasimir ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Antibacterial surfaces; Cytotoxicity; Infections; Innate inflammatory response; Medical devices; Silver nanoparticles

Indexed keywords

ADHESION; BACTERIA; BIOMEDICAL EQUIPMENT; CELL CULTURE; COATINGS; CYTOTOXICITY; IMPLANTS (SURGICAL); NANOPARTICLES;

ANTIBACTERIAL SURFACES; INFECTIONS; INFLAMMATORY RESPONSE; MEDICAL DEVICES; SILVER NANOPARTICLES;

SILVER;

ANTIINFECTIVE AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; SILVER NANOPARTICLE; THIOMALIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ANTIBACTERIAL COATING; ARTICLE; BACTERIUM CULTURE; CATHETER; CELL FUNCTION; CELL VIABILITY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG COATING; DRUG EFFICACY; FIBROBLAST; HUMAN; HUMAN CELL; IMMOBILIZATION; IMPLANT; IN VITRO STUDY; INNATE IMMUNITY; LIFESPAN; MACROPHAGE; MEDICAL DEVICE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; SURFACE PROPERTY; WOUND DRESSING;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ANTIBACTERIAL SURFACES; CYTOTOXICITY; INFECTIONS; INNATE INFLAMMATORY RESPONSE; MEDICAL DEVICES; SILVER NANOPARTICLES;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CELLS, CULTURED; COATED MATERIALS, BIOCOMPATIBLE; MACROPHAGES; METAL NANOPARTICLES; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PROSTHESES AND IMPLANTS; PSEUDOMONAS AERUGINOSA; SILVER; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 84896545626     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.02.033     Document Type: Article

References (54)

1. Vasilev K., Cook J., Griesser H.J. Antibacterial surfaces for biomedical devices. Expert Rev Med Devices 2009, 6:553-567.
2. Paitoonpong L., Wong C.K.B., Perl T.M. Healthcare-associated infections. Infectious disease epidemiology theory and practice 2013, 369-466. Jones&Bartlet Learning. K.E. Melson, C.M. Williams (Eds.).
3. Weston D. Types of healthcare associated infection. Infection prevention and control 2008, 85-109. John Wiley & Sons Ltd.
4. Campoccia D., Montanaro L., Arciola C.R. The significance of infection related to orthopedic devices and issues of antibiotic resistance. Biomaterials 2006, 27:2331-2339.
5. Anderson D.J., Pyatt D.G., Weber D.J., Rutala W.A. Statewide costs of health care-associated infections: estimates for acute care hospitals in North Carolina. Am J Infect Control 2013, 41:764-768.
6. Klevens R.M., Edwards J.R., Richards C.L., Horan T.C., Gaynes R.P., Pollock D.A., et al. Estimating health care-associated infections and deaths in U.S. Hospitals, 2002. Public Health Rep 2007, 122:160-166.
7. Graves N., Halton K., Paterson D., Whitby M. Economic rationale for infection control in Australian hospitals. Healthc Infect 2009, 14:81-88.
8. Gottenbos B., Busscher H.J., van der Mei H.C., Nieuwenhuis P. Pathogenesis and prevention of biomaterial centered infections. JMater Sci-Mater Med 2002, 13:717-722.
9. Halton K., Graves N. Economic evaluation and catheter-related bloodstream infections. Emerg Infect Dis 2007, 13:815-823.
10. Darouiche R.O. Current concepts-treatment of infections associated with surgical implants. NEngl J Med 2004, 350:1422-1429.
11. Pronovost P., Needham D., Berenholtz S., Sinopoli D., Chu H., Cosgrove S., et al. An intervention to decrease catheter-related bloodstream infections in the ICU. NEngl J Med 2006, 355:2725-2732.
12. O'Grady N.P., Alexander M., Burns L.A., Dellinger E.P., Garland J., Heard S.O., et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011, 52:e162-e193.
13. Jacobsen S., Stickler D., Mobley H., Shirtliff M. Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev 2008, 21:26-59.
14. Lai K.K., Fontecchio S.A. Use of silver-hydrogel urinary catheters on the incidence of catheter-associated urinary tract infections in hospitalized patients. Am J Infect Control 2002, 30:221-225.
15. Weinstein R.A., Darouiche R.O. Device-associated infections: a macroproblem that starts with microadherence. Clin Infect Dis 2001, 33:1567-1572.
16. Subbiahdoss G., Silva Domingues J., Kuijer R., Mei H., Busscher H. Bridging the gap between invitro and invivo evaluation of biomaterial-associated infections. Biomaterials associated infection 2013, 107-117. Springer, New York. T.F. Moriarty, S.A.J. Zaat, H.J. Busscher (Eds.).
17. Schierholz J.M., Beuth J. Implant infections: a haven for opportunistic bacteria. JHosp Infect 2001, 49:87-93.
18. Katsikogianni M., Missirlis Y. Concise review of mechanisms of bacterial adhesion to biomaterials and of techniques used in estimating bacteria-material interactions. Eur Cell Mater 2004, 8:37-57.
19. Noimark S., Dunnill C.W., Wilson M., Parkin I.P. The role of surfaces in catheter-associated infections. Chem Soc Rev 2009, 38:3435-3448.
20. Hetrick E.M., Schoenfisch M.H. Reducing implant-related infections: active release strategies. Chem Soc Rev 2006, 35:780-789.
21. Williams G.J. Antimicrobial surfaces 2013, 485-499. Russell, Hugo & Ayliffe's, Wiley-Blackwell.
22. Vasilev K., Sah V., Anselme K., Ndi C., Mateescu M., Dollmann B., et al. Tunable antibacterial coatings that support mammalian cell growth. Nano Lett 2010, 10:202-207.
23. Rai M., Yadav A., Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 2009, 27:76-83.
24. Chernousova S., Epple M. Silver as antibacterial agent: ion, nanoparticle, and metal. Angew Chem Int Ed 2013, 52:1636-1653.
25. Alexander J.W. History of the medical use of silver. Surg Infect 2009, 10:289-292.
26. Lansdown A. Silver I: its antibacterial properties and mechanism of action. JWound Care 2002, 11:125-130.
27. Reidy B., Haase A., Luch A., Dawson K.A., Lynch I. Mechanisms of silver nanoparticle release, transformation and toxicity: a critical review of current knowledge and recommendations for future studies and applications. Materials 2013, 6:2295-2350.
28. Klasen H. Historical review of the use of silver in the treatment of burns. I. Early uses. Burns J Int Soc Burn Inj 2000, 26:117-130.
29. Klasen H. Ahistorical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns 2000, 26:131-138.
30. Samberg M.E., Nancy A. 22 Silver nanoparticles in biomedical applications. Nanotoxicology: progress toward nanomedicine 2014, 405-421. CRC Press. 2nd ed.
31. Marambio-Jones C., Hoek E.M. Areview of the antibacterial effects of silver nanomaterials and potential implications for human health and the environment. JNanopart Res 2010, 12:1531-1551.
32. Chaloupka K., Malam Y., Seifalian A.M. Nanosilver as a new generation of nanoproduct in biomedical applications. Trends Biotechnol 2010, 28:580-588.
33. Ravindran A., Chandran P., Khan S.S. Biofunctionalized silver nanoparticles: advances and prospects. Colloids Surf B Biointerfaces 2013, 105:342-352.
34. Foldbjerg R., Autrup H. Mechanisms of silver nanoparticle toxicity. Arch Basic Appl Med 2013, 1:5-15.
35. Nadworny P.L., Wang J., Tredget E.E., Burrell R.E. Anti-inflammatory activity of nanocrystalline silver in a porcine contact dermatitis model. Nanomed Nanotech Biol Med 2008, 4:241-251.
36. Bhol K.C., Alroy J., Schechter P.J. Anti-inflammatory effect of topical nanocrystalline silver cream on allergic contact dermatitis in a guinea pig model. Clin Exp Dermatol 2004, 29:282-287.
37. Bhol K.C., Schechter P.J. Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. Br J Dermatol 2005, 152:1235-1242.
38. Locht L.J., Smidt K., Rungby J., Stoltenberg M., Larsen A. Uptake of silver from metallic silver surfaces induces cell death and a pro-inflammatory response in cultured J774 macrophages. Histol Histopathol 2011, 26:689-697.
39. Vasilev K., Michelmore A., Griesser H.J., Short R.D. Substrate influence on the initial growth phase of plasma-deposited polymer films. Chem Commun 2009, 3600-3602.
40. Vasilev K., Michelmore A., Martinek P., Chan J., Sah V., Griesser H.J., et al. Early stages of growth of plasma polymer coatings deposited from nitrogen- and oxygen-containing monomers. Plasma Process Polym 2010, 7:824-835.
41. Michelmore A., Martinek P., Sah V., Short R.D., Vasilev K. Surface morphology in the early stages of plasma polymer film growth from amine-containing monomers. Plasma Process Polym 2011, 8:367-372.
42. MacNeil S., Shepherd J., Smith L. Production of tissue-engineered skin and oral mucosa for clinical and experimental use. 3D cell culture 2011, 129-153. Springer.
43. Whittle J.D., Barton D., Alexander M.R., Short R.D. Amethod for the deposition of controllable chemical gradients. Chem Commun 2003, 1766-1767.
44. Vasilev K., Mierczynska A., Hook A.L., Chan J., Voelcker N.H., Short R.D. Creating gradients of two proteins by differential passive adsorption onto a PEG-density gradient. Biomaterials 2010, 31:392-397.
45. Love J.C., Estroff L.A., Kriebel J.K., Nuzzo R.G., Whitesides G.M. Self-assembled monolayers of thiolates on metals as a form of nanotechnology. Chem Rev 2005, 105:1103-1170.
46. Mierczynska A., Michelmore A., Tripathi A., Goreham R.V., Sedev R., Vasilev K. pH-tunable gradients of wettability and surface potential. Soft Matter 2012, 8:8399-8404.
47. Xiu Z.-m., Zhang Q.-b., Puppala H.L., Colvin V.L., Alvarez P.J. Negligible particle-specific antibacterial activity of silver nanoparticles. Nano Lett 2012, 12:4271-4275.
48. Becker R.O. Effects of electrically generated silver ions on human cells and wound healing. Electromagn Biol Med 2000, 19:1-19.
49. Jung W.K., Koo H.C., Kim K.W., Shin S., Kim S.H., Park Y.H. Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli. Appl Environ Microbiol 2008, 74:2171-2178.
50. Montali A. Antibacterial coating systems. Injury 2006, 37:S81-S86.
51. Vasilev K., Griesser S.S., Griesser H.J. Antibacterial surfaces and coatings produced by plasma techniques. Plasma Process Polym 2011, 8:1010-1023.
52. Zhu T., Vasilev K., Kreiter M., Mittler S., Knoll W. Surface modification of citrate-reduced colloidal gold nanoparticles with 2-mercaptosuccinic acid. Langmuir 2003, 19:9518-9525.
53. Park M.V.D.Z., Neigh A.M., Vermeulen J.P., de la Fonteyne L.J.J., Verharen H.W., Briedé J.J., et al. The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles. Biomaterials 2011, 32:9810-9817.
54. Park E.J., Yi J., Kim Y., Choi K., Park K. Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism. Toxicol InVitro 2010, 24:872-878.